Accounting for autism’s prevalence
Read recent Spectrum coverage about autism’s apparent rise in prevalence — and some of the potential explanations for it.
Read recent Spectrum coverage about autism’s apparent rise in prevalence — and some of the potential explanations for it.
This collection of Spectrum stories explores some of the evolving debates, challenges and methods used to make an autism diagnosis.
We take a look back at our 2023 coverage of blunders that prompted retractions in the neuroscience literature in this archival special report.
This collection of articles examines experimental gene therapies and methods devised over the past three years.
In this collection, we serve up Spectrum news stories about links between mitochondria and autism.
Take a look back at the year’s top developments in autism research and read about the field’s rising stars. Plus: Test your knowledge with our year-end quiz, and see which conferences we’re looking forward to in 2023.
For decades, two figures have dominated the history of autism studies. Today, newly excavated documents are calling into question the primacy of these men as founders of the field.
Spectrum’s Autism Drug Trial Tracker provides interactive, curated information about hundreds of clinical trials for autism and related conditions.
As 2021 comes to a close, Spectrum recaps some of the biggest trends in autism science this year: studies of sex differences, noncoding regions of the genome and points of convergence, as well as efforts to improve screening and participatory research.
Cannabis-derived drugs are approved to treat only a small number of autism-related conditions, but many autistic people and their families experiment with medical marijuana to ease autism traits. In this special report, Spectrum rounds up what the science says about cannabis and autism.